Potomac horse fever isolates

Patent metadata

Field	Value
Publication number	US-9764017-B2
Application number	US-201615094606-A
Country	US
Kind code	B2
Filing date	Apr 8, 2016
Priority date	Aug 30, 2010
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The present invention discloses novel isolates of Neorickettsia risticii , compositions comprising such isolates, vaccines and methods for using such vaccines against Potomac Horse Fever.

First claim

We claim:

1. A killed or inactivated Neorickettsia risticii ( N. risticii ) bacterium of the N. risticii Oregon strain that encodes:
a strain specific antigen #1 (SSA#1) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 2;
a strain specific antigen #2 (SSA#2) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 11; and
a strain specific antigen #3 (SSA#3) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 18.

2. An immunogenic composition comprising the killed or inactivated N. risticii bacterium of claim 1 and a carrier.

3. The immunogenic composition of claim 2 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.

4. The immunogenic composition of claim 3 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.

5. The killed or inactivated N. risticii bacterium of claim 1 , wherein the N. risticii bacterium is the N. risticii Oregon isolate having the ATCC deposit number PTA-11232.

6. A vaccine comprising an immunogenically effective amount of the killed or inactivated N. risticii bacterium of claim 5 and a carrier.

7. The vaccine of claim 6 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.

8. The vaccine of claim 7 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.

9. The killed or inactivated N. risticii bacterium of claim 5 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.

10. The killed or inactivated N. risticii bacterium of claim 9 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.

11. The killed or inactivated N. risticii bacterium of claim 1 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.

12. The killed or inactivated N. risticii bacterium of claim 11 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.

13. The killed or inactivated N. risticii of claim 1 comprising a nucleic acid comprising a nucleotide sequence encoding a SSA, wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and any combination thereof.

Assignees

• Intervet Inc

Inventors

• Purtle Lisa
• Mellencamp Mark
• Vaala Wendy

Classifications

• A61K2039/521

  inactivated (killed) · CPC title

• C12Q1/689

  for bacteria · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• C12R1/01

  Chemistry & Metallurgy · mapped topic